NasdaqGM:MDWD

Stock Analysis Report

Executive Summary

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications.

Snowflake

Fundamentals

Flawless balance sheet and undervalued.

Risks

  • MediWound has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has MediWound's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-15.0%

NasdaqGM:MDWD

-1.8%

US Pharmaceuticals

-1.0%

US Market


1 Year Return

-57.3%

NasdaqGM:MDWD

-6.6%

US Pharmaceuticals

-0.4%

US Market

MDWD underperformed the Pharmaceuticals industry which returned -6.6% over the past year.

MDWD underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

MDWDIndustryMarket
7 Day-15.0%-1.8%-1.0%
30 Day-27.0%-3.5%-3.3%
90 Day-37.4%-3.8%0.8%
1 Year-57.3%-57.3%-4.3%-6.6%1.9%-0.4%
3 Year-67.0%-67.0%7.9%0.6%39.4%30.4%
5 Year-61.3%-61.3%22.9%10.0%54.2%37.1%

Price Volatility Vs. Market

How volatile is MediWound's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MediWound undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

MediWound's share price is below the future cash flow value, and at a moderate discount (> 20%).

MediWound's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

MediWound is good value based on earnings compared to the US Pharmaceuticals industry average.

MediWound is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

MediWound is good value based on expected growth next year.


Price Based on Value of Assets

MediWound is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is MediWound expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

20.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

MediWound's revenue is expected to grow significantly at over 20% yearly.

MediWound's earnings are expected to grow significantly at over 20% yearly.

MediWound's revenue growth is expected to exceed the United States of America market average.

MediWound's earnings growth is expected to exceed the United States of America market average.

MediWound's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if MediWound will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has MediWound performed over the past 5 years?

18.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

MediWound's year on year earnings growth rate has been positive over the past 5 years.

MediWound has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

MediWound has become profitable in the last year making it difficult to compare the US Pharmaceuticals industry average.


Return on Equity

MediWound made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

MediWound used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

MediWound has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is MediWound's financial position?


Financial Position Analysis

MediWound is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

MediWound's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

MediWound has no debt.

MediWound currently has no debt however we can't compare to 5 years ago as we have no data for that period.

MediWound has no debt, it does not need to be covered by operating cash flow.

MediWound has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

MediWound has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is MediWound's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate MediWound's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate MediWound's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as MediWound has not reported any payouts.

Unable to verify if MediWound's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as MediWound has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of MediWound's salary, the management and board of directors tenure and is there insider trading?

5.0yrs

Average management tenure


CEO

Sharon Malka (47yo)

0.3yrs

Tenure

US$412,297

Compensation

Mr. Sharon Malka, C.P.A., MBA, has been the Chief Financial & Operation Officer at MediWound Ltd. since April 2007 and serves as its Chief Executive officer since May 31, 2019. Mr. Malka served as a Partne ...


CEO Compensation Analysis

Sharon's remuneration is about average for companies of similar size in United States of America.

Sharon's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.0yrs

Average Tenure

50yo

Average Age

The average tenure for the MediWound management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

2.2yrs

Average Tenure

58yo

Average Age

The average tenure for the MediWound board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Lior Rosenberg (73yo)

    Co-Founder & Chief Medical Technology Officer

    • Tenure: 18.6yrs
    • Compensation: $148.49k
  • Sharon Malka (47yo)

    Chief Executive Officer

    • Tenure: 0.3yrs
    • Compensation: $412.30k
  • Yaron Meyer (40yo)

    General Counsel & Corporate Secretary

    • Tenure: 5.7yrs
    • Compensation: $531.88k
  • Ety Klinger (57yo)

    Chief Research & Development Officer

    • Tenure: 5.3yrs
    • Compensation: $374.03k
  • Carsten Henke (53yo)

    Chief Commercial Officer of Europe

    • Tenure: 4.8yrs
    • Compensation: $405.11k
  • Boaz Gur-Lavie (45yo)

    Chief Financial Officer

    • Tenure: 0.2yrs
  • Roni Solomon

    Controller


Board Members

  • Steve Wills (62yo)

    Chairman of the Board of Directors

    • Tenure: 1.8yrs
  • Nissim Mashiach (58yo)

    Independent Director

    • Tenure: 2.2yrs
  • Sharon Kochan (51yo)

    Independent Director

    • Tenure: 2.2yrs
  • Ofer Gonen (45yo)

    Director

    • Tenure: 15.9yrs
  • Vickie Driver (65yo)

    Independent Director

    • Tenure: 2.3yrs
  • Assaf Segal

    Director

    • Tenure: 1.8yrs

Company Information

MediWound Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MediWound Ltd.
  • Ticker: MDWD
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$73.655m
  • Shares outstanding: 27.18m
  • Website: Click here

Number of Employees


Location

  • MediWound Ltd.
  • 42 Hayarkon Street
  • Yavne
  • 8122745
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDWDNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMar 2014
M8WDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2014

Biography

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 00:57
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.